Effects of CYP3A43 Expression on Cell Proliferation and Migration of Lung Adenocarcinoma and Its Clinical Significance

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2023 Jan 8

PMID 36613552

Authors

Qi-Yao Wei

Andy T Y Lau

Hai-Ying Mo

Qiu-Hua Zhong

Xiao-Yun Zhao

Fei-Yuan Yu

Jin Han

Yu-Yao Wu

Yan-Ming Xu

Affiliations

Soon will be listed here.

Abstract

The cytochrome P450s (CYP450s) include key oxidative enzymes involved in the metabolism of various carcinogens and anticancer drugs. Bioinformatic studies have demonstrated the association of CYP3A43 with liver cancer and ovarian cancer. However, the biological function of CYP3A43 in tumor progression remains unclear. To further reveal the role of CYP3A43 in tumor progression, we first analyzed the data from the UALCAN database and found that CYP3A43 was negatively correlated to the cancer staging and lymph node metastasis of lung adenocarcinoma (LUAD). We established stable CYP3A43-knockdown LUAD H1299 cell line and found that its knockdown enhanced cell proliferation, colony formation, and migration in vitro, and promoted the growth of tumor xenograft in vivo. Interestingly, when CYP3A43 was ectopically-expressed in the LUAD cell lines, decreased cell proliferation and ERK1/2 phosphorylation level were observed. Lastly, we also identified CYP3A43 co-expressed genes in LUAD from LinkedOmics database followed by GO and KEGG analyses. In conclusion, our results indicate the unprecedented role of CYP3A43 in the suppression of LUAD and provide new possibilities for targeted therapy of this life-threatening disease.

Citing Articles

Gene Expression Reprogramming by Citrate Supplementation Reduces HepG2 Cell Migration and Invasion.

Miglionico R, Matera I, Ventola G, Marchese G, Abruzzese V, Monne M Int J Mol Sci. 2024; 25(12).

PMID: 38928215 PMC: 11203947. DOI: 10.3390/ijms25126509.

Targeting Cytochrome P450 Enzymes in Ovarian Cancers: New Approaches to Tumor-Selective Intervention.

Al-Saraireh Y, Alshammari F, Abu-Azzam O, Al-Dalain S, Al-Sarayra Y, Haddad M Biomedicines. 2023; 11(11).

PMID: 38001897 PMC: 10669316. DOI: 10.3390/biomedicines11112898.

Advances in the application of computational pathology in diagnosis, immunomicroenvironment recognition, and immunotherapy evaluation of breast cancer: a narrative review.

Luo J, Li X, Wei K, Chen G, Xiong D J Cancer Res Clin Oncol. 2023; 149(13):12535-12542.

PMID: 37389595 DOI: 10.1007/s00432-023-05002-8.

Comparison of Human Eukaryotic Translation Initiation Factors 5A1 and 5AL1: Identification of Amino Acid Residues Important for EIF5A1 Lysine 50 Hypusination and Its Protein Stability.

Wu Y, Wu G, Cai N, Xu Y, Lau A Int J Mol Sci. 2023; 24(7).

PMID: 37047039 PMC: 10093921. DOI: 10.3390/ijms24076067.

The effects of the prognostic biomarker SAAL1 on cancer growth and its association with the immune microenvironment in lung adenocarcinoma.

Tong S, Jiang N, Wan J, Chen C, Wang S, Wu C BMC Cancer. 2023; 23(1):275.

PMID: 36973678 PMC: 10041717. DOI: 10.1186/s12885-023-10741-5.

References

Wang J, Duncan D, Shi Z, Zhang B . WEB-based GEne SeT AnaLysis Toolkit (WebGestalt): update 2013. Nucleic Acids Res. 2013; 41(Web Server issue):W77-83. PMC: 3692109. DOI: 10.1093/nar/gkt439. View

McCubrey J, Steelman L, Chappell W, Abrams S, Wong E, Chang F . Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta. 2006; 1773(8):1263-84. PMC: 2696318. DOI: 10.1016/j.bbamcr.2006.10.001. View

Sun L, Fan X . Expression of cytochrome P450 2A13 in human non-small cell lung cancer and its clinical significance. J Biomed Res. 2013; 27(3):202-7. PMC: 3664726. DOI: 10.7555/JBR.27.20120019. View

Liang G, Fan W, Luo H, Zhu X . The emerging roles of artificial intelligence in cancer drug development and precision therapy. Biomed Pharmacother. 2020; 128:110255. DOI: 10.1016/j.biopha.2020.110255. View

Zimmerman S, Das A, Wang S, Julian R, Gandhi L, Wolf J . 2017-2018 Scientific Advances in Thoracic Oncology: Small Cell Lung Cancer. J Thorac Oncol. 2019; 14(5):768-783. DOI: 10.1016/j.jtho.2019.01.022. View

Denisenko T, Budkevich I, Zhivotovsky B . Cell death-based treatment of lung adenocarcinoma. Cell Death Dis. 2018; 9(2):117. PMC: 5833343. DOI: 10.1038/s41419-017-0063-y. View

Zhou B, Der C, Cox A . The role of wild type RAS isoforms in cancer. Semin Cell Dev Biol. 2016; 58:60-9. PMC: 5028303. DOI: 10.1016/j.semcdb.2016.07.012. View

Vasaikar S, Straub P, Wang J, Zhang B . LinkedOmics: analyzing multi-omics data within and across 32 cancer types. Nucleic Acids Res. 2017; 46(D1):D956-D963. PMC: 5753188. DOI: 10.1093/nar/gkx1090. View

Yu T, Wang X, Zhu G, Han C, Su H, Liao X . The prognostic value of differentially expressed CYP3A subfamily members for hepatocellular carcinoma. Cancer Manag Res. 2018; 10:1713-1726. PMC: 6025769. DOI: 10.2147/CMAR.S159425. View

10.

Gellner K, Eiselt R, Hustert E, Arnold H, Koch I, Haberl M . Genomic organization of the human CYP3A locus: identification of a new, inducible CYP3A gene. Pharmacogenetics. 2001; 11(2):111-21. DOI: 10.1097/00008571-200103000-00002. View

11.

Li H, Wang T, Li X, Li N, Huang D, Chen Q . Overexpression of cyclin L2 induces apoptosis and cell-cycle arrest in human lung cancer cells. Chin Med J (Engl). 2007; 120(10):905-9. View

12.

Ye Z, Huang Y, Ke J, Zhu X, Leng S, Luo H . Breakthrough in targeted therapy for non-small cell lung cancer. Biomed Pharmacother. 2020; 133:111079. DOI: 10.1016/j.biopha.2020.111079. View

13.

van Eijk M, Boosman R, Schinkel A, Huitema A, Beijnen J . Cytochrome P450 3A4, 3A5, and 2C8 expression in breast, prostate, lung, endometrial, and ovarian tumors: relevance for resistance to taxanes. Cancer Chemother Pharmacol. 2019; 84(3):487-499. PMC: 6682574. DOI: 10.1007/s00280-019-03905-3. View

14.

Downie D, McFadyen M, Rooney P, Cruickshank M, Parkin D, Miller I . Profiling cytochrome P450 expression in ovarian cancer: identification of prognostic markers. Clin Cancer Res. 2005; 11(20):7369-75. DOI: 10.1158/1078-0432.CCR-05-0466. View

15.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

16.

Salvador-Barbero B, Alvarez-Fernandez M, Zapatero-Solana E, El Bakkali A, Menendez M, Lopez-Casas P . CDK4/6 Inhibitors Impair Recovery from Cytotoxic Chemotherapy in Pancreatic Adenocarcinoma. Cancer Cell. 2020; 38(4):584. DOI: 10.1016/j.ccell.2020.09.012. View

17.

Justenhoven C, Winter S, Hamann U, Haas S, Fischer H, Pesch B . The frameshift polymorphism CYP3A43_74_delA is associated with poor differentiation of breast tumors. Cancer. 2010; 116(23):5358-64. DOI: 10.1002/cncr.25508. View

18.

Ma J, Ward E, Smith R, Jemal A . Annual number of lung cancer deaths potentially avertable by screening in the United States. Cancer. 2013; 119(7):1381-5. DOI: 10.1002/cncr.27813. View

19.

Zeigler-Johnson C, Friebel T, Walker A, Wang Y, Spangler E, Panossian S . CYP3A4, CYP3A5, and CYP3A43 genotypes and haplotypes in the etiology and severity of prostate cancer. Cancer Res. 2004; 64(22):8461-7. DOI: 10.1158/0008-5472.CAN-04-1651. View

20.

Lau A, Xu Y . Regulation of human mitogen-activated protein kinase 15 (extracellular signal-regulated kinase 7/8) and its functions: A recent update. J Cell Physiol. 2018; 234(1):75-88. DOI: 10.1002/jcp.27053. View